AMGNAmgen
Price
+54%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growing in the filings, the market undecided.
Amgen Inc. (including its subsidiaries, referred to as “Amgen,” “the Company,” “we,” “our” or “us”) discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. We focus on areas of high unmet medical need and leverage our expertise to strive for solutions that dramatically improve people’s lives, while also reducing the social and economic burden of disease. We helped launch the biotechnology industry more than 45 years ago and have grown to be one of the world’s leading independent biotechnology companies.
In the company’s own words · 10-K filed Feb 13, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Amgen (AMGN) reported revenue of $10.1B in Q2 2026 (quarter ended Jun 30, 2026), up 9.5% from the same quarter a year earlier. That came with a gross margin of 72% and net income of $2.38B (24% of revenue). For the full year FY2025, revenue was $36.8B (+10.0% year on year) and net income $7.71B. Its largest product in Q2 2026 was Other Products at $1.28B, 17% of the disclosed total, ahead of Enbrel at 7.6%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 31, 2026In July 2026, Amgen Inc. (the "Company") identified unauthorized activity involving data stored in cloud environments hosted by third-party cloud service providers.Material cybersecurity incident · Form 8-K
- May 19, 2026Retirement of Peter H. Griffith, Chief Financial Officer On May 19, 2026, Amgen Inc. (the “Company”) publicly announced that Peter H. Griffith will retire from the role of the Company’s Executive Vice President and Chief Financial Officer, effective August 31, 2026.Director or officer change · Form 8-K
- Apr 22, 2026On April 22, 2026, Amgen Inc. (the “Company”) publicly announced that David M. Reese is retiring from the role of the Company’s Executive Vice President and Chief Technology Officer.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $7.51BThe company’s own SEC segment disclosure.
- Other Products$1.28B17%
- Enbrel$574.0M8%
- EVENITY$550.0M7%
- TEPEZZA$520.0M7%
- Product And Service Other$517.0M7%
- Repathaevolocumab$510.0M7%
- Other (12)$3.55B47%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
The closest names by size in the same industry